A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response

BACKGROUND: Current first-line standard of therapy for metastatic urothelial carcinoma is platinum-based combination chemotherapy. Pembrolizumab in phase III has demonstrated a promising overall response rate of 21.1% in patients with progression or recurrence after platinum-based chemotherapy. Prec...

Descripción completa

Detalles Bibliográficos
Autores principales: Sundahl, Nora, De Wolf, Katrien, Rottey, Sylvie, Decaestecker, Karel, De Maeseneer, Daan, Meireson, Annabel, Goetghebeur, Els, Fonteyne, Valérie, Verbeke, Sofie, De Visschere, Pieter, Reynders, Dries, Van Gele, Mireille, Brochez, Lieve, Ost, Piet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5492401/
https://www.ncbi.nlm.nih.gov/pubmed/28662677
http://dx.doi.org/10.1186/s12967-017-1251-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5492401/
https://www.ncbi.nlm.nih.gov/pubmed/28662677
http://dx.doi.org/10.1186/s12967-017-1251-3

Ejemplares similares